213 related articles for article (PubMed ID: 2119878)
21. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
Levin L; Simon R; Hryniuk W
J Natl Cancer Inst; 1993 Nov; 85(21):1732-42. PubMed ID: 8411257
[TBL] [Abstract][Full Text] [Related]
22. Modulation and intensification of a cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin ovarian cancer regimen.
Bruckner HW; Cohen CJ; Feuer E; Holland JF
Obstet Gynecol; 1989 Mar; 73(3 Pt 1):349-56. PubMed ID: 2492648
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy of drug-resistant ovarian cancer: a Southwest Oncology Group Study.
Laufman LR; Green JB; Alberts DS; O'Toole R; Hilgers RD; Young DC; Lin F; Rivkin SE
J Clin Oncol; 1986 Sep; 4(9):1374-9. PubMed ID: 3091778
[TBL] [Abstract][Full Text] [Related]
24. Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.
Razis DV; Poulakou E; Petounis A; Papadimitriou G; Kosmides P; Delides G
Oncology; 1982; 39(4):205-8. PubMed ID: 6806735
[TBL] [Abstract][Full Text] [Related]
25. [Chemotherapy of epithelial ovarian carcinoma].
Bruntsch U; Gallmeier WM
MMW Munch Med Wochenschr; 1983 Nov; 125(44):993-5. PubMed ID: 6417517
[No Abstract] [Full Text] [Related]
26. Chemotherapy of ovarian cancer.
Ozols RF; Young RC
Semin Oncol; 1984 Sep; 11(3):251-63. PubMed ID: 6435250
[No Abstract] [Full Text] [Related]
27. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
[TBL] [Abstract][Full Text] [Related]
28. Malignant mixed mesodermal tumors of the uterus and ovary treated with cisplatin-based combination chemotherapy.
Grosh WW; Jones HW; Burnett LS; Greco FA
Gynecol Oncol; 1986 Nov; 25(3):334-9. PubMed ID: 3023205
[TBL] [Abstract][Full Text] [Related]
29. Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas.
Edmonson JH; McCormack GW; Fleming TR; Cullinan SA; Krook JE; Malkasian GD; Podratz KC; Mailliard JA; Jefferies JA; Barlow JF
Cancer Treat Rep; 1985 Nov; 69(11):1243-8. PubMed ID: 3937598
[TBL] [Abstract][Full Text] [Related]
30. Treatment of advanced ovarian cancer with sequential combination chemotherapy.
Griffin TW; Hunter RA; Cederbaum AI; Tak WK; Ward AD; Schwartz JH; Halpin TF; Strauss GM; Meyer RN; Liepman MK
Cancer; 1987 Nov; 60(9):2150-5. PubMed ID: 2830953
[TBL] [Abstract][Full Text] [Related]
31. The cyclophosphamide, hexamethylmelamine, 5 fluorouracil (CHF) regimen in the treatment of advanced and recurrent ovarian cancer.
Posada JG; Marantz AB; Yeung KY; Smith FP; Delgado G; Edwards BK; Schein PS
Gynecol Oncol; 1985 Jan; 20(1):23-31. PubMed ID: 3917421
[TBL] [Abstract][Full Text] [Related]
32. Intraperitoneal chemotherapy for advanced ovarian cancer.
Lucas WE; Markman M; Howell SB
Am J Obstet Gynecol; 1985 Jun; 152(4):474-8. PubMed ID: 3925784
[TBL] [Abstract][Full Text] [Related]
33. Schedule and dosage modification of a cyclophosphamide, hexamethylmelamine, doxorubicin, cisplatin combination chemotherapy regimen for refractory ovarian cancer.
Bruckner HW; Cohen CJ; Bhardwaj S; Feuer E; Chesser MR; Holland JF
Eur J Cancer Clin Oncol; 1989 Sep; 25(9):1273-9. PubMed ID: 2509207
[TBL] [Abstract][Full Text] [Related]
34. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin neuropathy: a prospective clinical and electrophysiological study in Chinese patients with ovarian carcinoma.
Fu KK; Kai EF; Leung CK
J Clin Pharm Ther; 1995 Jun; 20(3):167-72. PubMed ID: 7593379
[TBL] [Abstract][Full Text] [Related]
36. Use of cis-platinum in the treatment of ovarian carcinoma. Clinical results and evaluation of nephrotoxicity.
Giannattasio M; Rizzi R; Coratelli P; Restaino A; Selvaggi L; Ferreri R; Orlando E; Ierardi GM; Granata A; Bettocchi S
Eur J Gynaecol Oncol; 1983; 4(1):41-3. PubMed ID: 6407837
[No Abstract] [Full Text] [Related]
37. Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma.
Leonard RC; Smart GE; Livingstone JR; Cornbleet MA; Kerr GR; Fletcher S; Webb JN; Smyth JF
Cancer Chemother Pharmacol; 1989; 23(2):105-10. PubMed ID: 2491962
[TBL] [Abstract][Full Text] [Related]
38. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
Shapiro JD; Rothenberg ML; Sarosy GA; Steinberg SM; Adamo DO; Reed E; Ozols RF; Kohn EC
Cancer; 1998 Nov; 83(9):1980-8. PubMed ID: 9806657
[TBL] [Abstract][Full Text] [Related]
39. Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens.
Vogl SE; Pagano M; Kaplan BH; Greenwald E; Arseneau J; Bennett B
Cancer; 1983 Jun; 51(11):2024-30. PubMed ID: 6404547
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors: cisplatin regimens for patients with ovarian cancer after failure of chemotherapy.
Bruckner HW; Cohen CJ; Feuer E; Wallach RC; Kabakow B; Holland JF
Obstet Gynecol; 1987 Jan; 69(1):114-20. PubMed ID: 3099235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
